Tradestie Institutional Equity Comparison Engine

ACAD vs AQB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ACAD trades at 16.9x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus AQB at N/M Forward P/E and 0.0% operating margin (-93.5% YoY). In options structure, ACAD sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro) against AQB sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
ACAD 16.9x vs AQB N/M Fwd P/E
Growth & Margin Winner ACAD
Op Margin 10.2% vs 0.0% ยท YoY +22.8% vs -93.5%
Momentum & Technical Winner ACAD
1Y -23.7% vs -23.6% ยท 52W Pos 16% vs 11%
Options & Structure Winner ACAD
BREAKDOWN (9th %ile IV) vs BREAKDOWN (N/A IV)
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$18.32
-1.87% 1D
Market Cap $3.2B
1M Return -7.47%
1Y Return -23.73%
Forward P/E 16.9x
Unified AI Score
47.9 / 100 HOLD
Tech 48.0 Fund 57.0 Flow 65.0 Mom 60.0
AQB NASDAQ
AquaBounty Technologies, Inc.
Fishing, Hunting And Trapping
$0.82
+2.01% 1D
Market Cap $9.7M
1M Return -21.37%
1Y Return -23.57%
Forward P/E N/M
Unified AI Score
44.6 / 100 HOLD
Tech 33.0 Fund 49.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACAD -23.73% AQB -23.57% Spread: +0.16 pp (AQB Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ACAD Revenue AQB Revenue ACAD Op. Margin AQB Op. Margin Margin Edge
FY2018 $220M $0M -110.6% -12264.6% ACAD
FY2019 $340M $0M -72.7% -7057.3% ACAD
FY2020 $440M $0M -64.9% -12727.1% ACAD
FY2021 $480M $0M -35.2% -1883.0% ACAD
FY2022 $520M $0M -43.2% -711.6% ACAD
FY2023 $730M $0M -10.1% -552.9% ACAD
FY2024 $960M N/A 24.1% N/A ACAD
FY2025 $1.07B N/A 9.8% N/A ACAD

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACAD (10) vs AQB (0)
Institutional Metric ACAD AQB Criterion Row Winner
Market Capitalization Scale $3.2B $9.7M Larger Scale ACAD
Trailing P/E Ratio Valuation 8.8x N/M Lower Multiple ACAD
Forward P/E Ratio Valuation 16.9x N/M Lower Multiple ACAD
Revenue Growth (YoY) Growth +22.8% -93.5% Higher Growth ACAD
Operating Margin (TTM) Profitability 10.2% 0.0% Higher Margin ACAD
Net Profit Margin Profitability 30.1% 0.0% Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency 31.4% -68.9% Higher ROE ACAD
52-Week Range Position Momentum 16% ($16โ€“$31) 11% ($1โ€“$2) Stronger Trend ACAD
Beta / 30D Volatility Risk Regime 0.16ฮฒ ยท 90% Vol 0.93ฮฒ ยท 117% Vol Lower Realized Risk ACAD
Unified Institutional Score Composite Signal 47.9 / 100 (HOLD) 44.6 / 100 (HOLD) Higher Composite ACAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACAD vs AQB Buy Guide
ACAD BREAKDOWN
59d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AQB BREAKDOWN
69d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AQB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACAD nor AQB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.